International legal practice Osborne Clarke has advised Universal Health Services, Inc (“ UHS“) on its £377 million acquisition of Cambian Group plc’s Adult Services Division. UHS is a Fortune 500 company based in King of Prussia, Pennsylvania and is one of the largest hospital management companies in the United States...

UK regulatory timeline The regulatory landscape in the UK is diverse and complex. Every business has to deal with a host of different regulatory regimes and regulators, each with its own approach to compliance and enforcement. To help you keep up to date with the regulatory changes in the areas...

Drafting and using purchase and licensing agreements in English has been standard practice for decades, even for European companies located in non-English-speaking regions. This is particularly true for internationally operating pharmaceutical companies. That typically leads to the adoption of classic contractual clauses from Anglo-American law, without necessarily understanding the specific...

The General Court of the Court of Justice of the EU recently rejected in Case T-12/22 an appeal made by Hasco TM sp. Z o.o. sp.k to rely on their Polish registration for Naturkaps to invalidate Esi SRL's EU trade mark Naturcaps. This was because Hasco failed to show genuine...

The Supreme Court has ratified the binding nature of the reports issued by the Ministry of Science and Innovation in relation to the application of deductions for technological innovation projects and associated expenses. It also limits the tax authorities' ability to contradict these reports by means of internal documents. In...

For the first time, the Italian Ministry of Health has published a Transparency List for generic veterinary medicinal products. In addition to this, in a few days a legislative decree adapting Italian legislation to the provisions of Regulation (EU) 2019/6 will enter into force. The Transparency List On 15 December...

The Italian Medicines Agency (AIFA) published in late August its "Guideline on regulatory simplification and decentralised elements for conducting clinical trials of medicinal products in accordance with regulation (EU) no 536/2014". The scope of this guideline, which confirms full applicability in Italy of relevant EU recommendation/guidelines, concerns organisational aspects. It...

The European Union's pioneering legal framework for artificial intelligence (AI), which was approved by the Council of the EU in May, has signalled a significant shift in AI regulation internationally. Unlike previous legislation on industrial goods, the EU AI Act extends its reach to include system deployers and imposes a...

On 5 June this year, a measure of the Italian Data Protection Authority no. 298/2024) was published in the Official Gazette, which dictates the guarantees to be observed for the processing of health data for medical, biomedical and epidemiological research purposes, in cases where it is not possible to obtain...

Negotiated with the Member States in December 2023, the EU Artificial Intelligence (AI) Act, the regulation laying down harmonised rules on the transformative technology, gained approval from the European Parliament in March 2024. The EU AI Act awaits final adoption and endorsement by the Council of the EU, which is...